Status of HPV vaccine introduction and barriers to country uptake

K E Gallagher; D S LaMontagne; D Watson-Jones

doi:10.1016/j.vaccine.2018.02.003

Status of HPV vaccine introduction and barriers to country uptake

Vaccine. 2018 Aug 6;36(32 Pt A):4761-4767. doi: 10.1016/j.vaccine.2018.02.003. Epub 2018 Mar 23.

Authors

K E Gallagher¹, D S LaMontagne², D Watson-Jones³

Affiliations

¹ London School of Hygiene & Tropical Medicine, Clinical Research Department, UK.
² PATH, Centre for Vaccine Innovation & Access, Seattle, USA. Electronic address: [email protected].
³ London School of Hygiene & Tropical Medicine, Clinical Research Department, UK; Mwanza Intervention Trials Unit, Mwanza, Tanzania.

PMID: 29580641
DOI: 10.1016/j.vaccine.2018.02.003

Abstract

During the last 12 years, over 80 countries have introduced national HPV vaccination programs. The majority of these countries are high or upper-middle income countries. The barriers to HPV vaccine introduction remain greatest in those countries with the highest burden of cervical cancer and the most need for vaccination. Innovation and global leadership is required to increase and sustain introductions in low income and lower-middle income countries.

Keywords: HPV; Human papillomavirus; Low income countries; Uptake; Vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Child
Costs and Cost Analysis
Developing Countries / economics*
Female
Global Health / economics
Humans
Income
Mass Vaccination / economics*
Papillomavirus Infections / epidemiology
Papillomavirus Infections / prevention & control*
Papillomavirus Vaccines / administration & dosage*
Papillomavirus Vaccines / therapeutic use
Uterine Cervical Neoplasms / epidemiology
Uterine Cervical Neoplasms / prevention & control*
Uterine Cervical Neoplasms / therapy

Substances

Papillomavirus Vaccines